Basic Information

Gene symbol HA Synonyms None Type of gene protein-coding
Description haemagglutinin

Gene symbol NEU1 Synonyms NANH, NEU, SIAL1 Type of gene protein-coding
Description neuraminidase 1

GTO ID GTC0565
Trial ID NCT05333289
Disease Seasonal Influenza
Altered gene HA|NEU1
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment mRNA-1020;mRNA-1030;mRNA-1010
Co-treatment Flublok
PhasePhase1|Phase2
Recruitment statusCompleted
TitlePhase 1/2, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines in Healthy Adults
Year2022
CountryUnited States
Company sponsorModernaTX, Inc.
Other ID(s)mRNA-1020-P101
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: Flublok
Administration route intramuscular injection
Dosage Flublock, on Day 1
Pts 71
Age Adult, Older_Adult
Adverse reactions 1/72(All-cause mortality); 2/71(Injury, poisoning and procedural complications)
Cohort2: mRNA-1010
Administration route intramuscular injection
Dosage mRNA-1010, on Day 1
Pts 72
Age Adult, Older_Adult
Adverse reactions 0/71(All-cause mortality); 1/71(Gastrointestinal disorders)
Cohort3: mRNA-1030_Dose Level A
Administration route intramuscular injection
Dosage mRNA-1030, Dose Level A, on Day 1
Pts 72
Age Adult, Older_Adult
Adverse reactions 0/71(All-cause mortality); 1/71(Gastrointestinal disorders)
Cohort4: mRNA-1020_Dose Level A
Administration route intramuscular injection
Dosage mRNA-1020, Dose Level A, on Day 1
Pts 71
Age Adult, Older_Adult
Adverse reactions 0/72(All-cause mortality); 1/71(Injury, poisoning and procedural complications)
Cohort5: mRNA-1030_Dose Level B
Administration route intramuscular injection
Dosage mRNA-1030, Dose Level B, on Day 1
Pts 72
Age Adult, Older_Adult
Adverse reactions 0/72(All-cause mortality); 1/72(Psychiatric disorders)
Cohort6: mRNA-1020_Dose Level B
Administration route intramuscular injection
Dosage mRNA-1020, Dose Level B, on Day 1
Pts 71
Age Adult, Older_Adult
Adverse reactions 0/71(All-cause mortality); 0/67
Cohort7: mRNA-1030_Dose Level C
Administration route intramuscular injection
Dosage mRNA-1030, Dose Level C, on Day 1
Pts 71
Age Adult, Older_Adult
Adverse reactions 0/72(All-cause mortality); 2/72(Injury, poisoning and procedural complications; Nervous system disorders)
Cohort8: mRNA-1020_Dose Level C
Administration route intramuscular injection
Dosage mRNA-1020, Dose Level C, on Day 1
Pts 72
Age Adult, Older_Adult
Adverse reactions 0/71(All-cause mortality); 4/70(Cardiac disorders; Gastrointestinal disorders; Hepatobiliary disorders; Infections and infestations)

Relationship Graph

Overview of Knowledge Graph